FDA Panel Rejects Novartis AG (NVS) Drug for Gout
6/21/2011 3:02:01 PM
A U.S. advisory panel on Tuesday rejected a Novartis AG drug for gout over concerns about side effects, a setback for the company's efforts to expand use of the medicine.
A committee of Food and Drug Administration advisers voted 11-1 against recommending approval of Ilaris for treating gout attacks. The panel also voted 12-0 against Ilaris for delaying and reducing the frequency of future attacks.